NCT04004299 (SELFIE) is a NA clinical trial of HCV RNA self-test in Hepatitis C Recurrent, sponsored by Erasmus Medical Center.

Who is sponsoring NCT04004299?

NCT04004299 is sponsored by Erasmus Medical Center.

What drugs are being tested in NCT04004299?

Interventions in NCT04004299: HCV RNA self-test.

What condition does NCT04004299 study?

NCT04004299 studies Hepatitis C Recurrent, HIV-1-infection.

Is NCT04004299 still recruiting?

NCT04004299 is currently status unknown. Last updated 12 August 2019.

Last reviewed 2019-08-12 · How we verify

NCT04004299: SELFIE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Self-testing for HCV Re-infection in MSM

Status unknown NA Last updated 12 August 2019

What this trial tests

NA trial testing HCV RNA self-test in Hepatitis C Recurrent in 200 participants. Status unknown.

Timeline

18 July 2019

Primary endpoint
28 February 2023

30 June 2023

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	200
Start date	18 July 2019
Primary completion	28 February 2023
Estimated completion	30 June 2023
Sites	7 locations across Netherlands

Drugs / interventions tested

HCV RNA self-test

Conditions studied

Hepatitis C Recurrent — all drugs for Hepatitis C Recurrent →
HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

Erasmus Medical Center

Who can join

18 and older, male only, with Hepatitis C Recurrent or HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HIV+MSM (men who have sex with men) that have been cured of a hepatitis C viral infection (HCV) are at risk for HCV re-infection (5-10% per year). One intervention to reduce HCV incidence in this population may be to decrease the time to diagnosis of HCV re-infections in order to decrease the duration that these re-infected patients may transmit their HCV to sex partners. Diagnosis of HCV re-infection is followed by counseling on transmission risk in combination with prompt initiation of HCV therapy, which will prevent new HCV infections on the population level. In this study the investigators evaluate the effect and feasibility of more frequent and home-based testing for HCV on the time to diagnosis and treatment of HCV re-infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04004299 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 12 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04004299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing